pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

906 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1566Endpoints1225BioSpace565Fierce Biotech562BioPharma Dive467raps192onclive165fda recalls
therapy area
allOncology10451Rare Disease2757Immunology2463Cardiology2287Hematology1887Pulmonology1875Vaccines
  • Oliva LLC recalls 250 units of Riad's Oliva to Go dips over undeclared sesame
    Oliva LLC of Bethlehem, Connecticut announced a voluntary recall of about 250 units of its Riad's Oliva to Go line, including Baba Ghanouj, Spicy Baba Ghanouj and Hummus. The recall was triggered…
    fda recalls · 12d agoCRLNegative↗ source
  • Krasnyi Oktyabr Recalls Starfish Seafood Trio Over Listeria Risk
    Krasnyi Oktyabr Inc. of Brooklyn, New York announced a voluntary recall of its Starfish Seafood Trio, which includes cold smoked salmon, halibut and trout packaged in 8‑oz vacuum‑sealed packs. The…
    fda recalls · 12d agoCRLNegative↗ source
← prev
page 4 of 37
next →
103
fda medwatch93
globenewswire health73
fda press54
1646
Psychiatry & CNS1107
Ophthalmology871
Endocrinology & Metabolism691
Pain656
Nephrology645
  • Krasnyi Oktyabr Inc. Recalls Starfish Seafood Premium Cold Smoked Norwegian Salmon Sliced (227g/8oz) Because of Possible Health Risk
    Krasnyi Oktyabr Inc. of Brooklyn, New York, is voluntarily recalling STARFISH SEAFOOD PREMIUM COLD SMOKED NORWEGIAN SALMON SLICED (227g/8oz) packages, because the product has the potential to be co…
    fda recalls · 12d ago↗ source
  • Argenx halts late-stage Vyvgart trial in Sjogren’s disease after futility finding, shares tumble 13%
    Argenx announced it is ending the Phase 3 UNITY trial of its Vyvgart Hytrulo injection in Sjogren’s disease after an independent data monitoring committee concluded the study would not meet its pri…
    BioSpace · 13d agoNegative readoutNegative↗ source
  • Par Health recalls two lots of Brevital Sodium injection over cellulose particles
    Par Health announced a voluntary recall of two lots of its Brevital® Sodium 500 mg/vial for injection after detecting particulate matter identified as cellulose. The recall is being executed at th…
    fda recalls · 13d agoRegulatoryNegative↗ source
  • Newron reports five deaths in schizophrenia trial as FDA keeps hold on evenamide study
    Newron Pharmaceuticals disclosed that five participants have died in its late-stage schizophrenia trial, with four deaths among those receiving the investigational drug evenamide and one death amon…
    BioSpace · 13d agoRegulatoryNegative↗ source
  • Zealand Pharma’s petrelintide shows 9% weight loss in Phase 2 but fails to improve blood sugar, analysts unimpressed
    Zealand Pharma, in partnership with Roche, reported results from the Phase 2 ZUPREME-2 trial of petrelintide, a long‑acting human amylin analog, in 220 obese or overweight patients with type 2 diab…
    BioSpace · 13d agoNegative readoutNeutral↗ source
  • Matchpoint Therapeutics raises $150 million Series B to move oral T-cell modulator MPT-062 toward clinical trials
    Matchpoint Therapeutics announced the closing of a $150 million Series B financing round. The round was co-led by Nextech Invest and Norwest, with participation from Sanofi Ventures and several exi…
    BioSpace · 13d agoDealPositive↗ source
  • ARM playbook proposes data reuse to slash gene-editing R&D costs and broaden rare-disease therapies
    The Alliance for Regenerative Medicine released a new playbook that outlines how developers of gene‑editing therapies can reuse existing data to lower research and development expenses. The guidanc…
    BioSpace · 13d agoRegulatoryPositive↗ source
  • Venture debt becomes central financing option for late-stage European biotech
    BioSpace’s Denatured podcast recently featured Jennifer McMahon of Seroba and Joey Mason of Claret Capital discussing the growing role of venture debt in European biotech. The guests explained tha…
    BioSpace · 13d agoPositive↗ source
  • Rare disease biotech firms expand teams as FDA approvals boost pipelines
    Several biotech companies focused on rare diseases are actively hiring, offering opportunities for professionals interested in this niche therapeutic area. The article highlights four firms that ar…
    BioSpace · 13d agoPositive↗ source
  • Q3 biopharma layoffs drop 90% year-over-year, affecting about 1,800 workers
    Biopharma companies reduced their layoff activity in the third quarter, with the number of employees affected falling about 90% compared with the same period last year. According to BioSpace data,…
    BioSpace · 13d agoLayoffsNeutral↗ source
  • Eli Lilly’s trillion-dollar market cap mirrors Dodgers’ big-spending dominance
    The piece draws a parallel between Eli Lilly and the Los Angeles Dodgers, noting that both organizations dominate their fields by spending heavily. Lilly recently became the first pharmaceutical co…
    BioSpace · 13d agoPositive↗ source
  • Gardeners Basics Recalls Waltham 29 Broccoli Sprouting Seeds Due to Possible Salmonella Contamination
    October 8, 2026, Gardeners Basics of Spanish Fork, Utah, is recalling one-pound bags of broccoli sprouting seeds because they may be contaminated with Salmonella, an organism which can cause seriou…
    fda recalls · 12d ago↗ source
  • Merck barred from making subcutaneous Keytruda in 8 European countries
    With the patent court siding with Halozyme, Merck faces restrictions on a product that won approval in Europe last year.
    BioSpace · 13d ago↗ source
  • Cerevance's solengepras cuts Parkinson off-time by 0.6 hours in Phase 3, advancing toward FDA review
    Cerevance, a spinout from Takeda, reported that a high 150‑mg dose of its Parkinson's drug solengepras reduced daily "off time" by an average of 0.61 hours compared with placebo in the Phase 3 ARIS…
    BioSpace · 14d agoPositive readoutPositive↗ source
  • Epkinly shows 51% lower risk of progression in frontline DLBCL trial, boosting hopes for expanded approval
    New Phase 3 data from the Epkinly and R-CHOP combination in diffuse large B cell lymphoma showed a 51% reduction in the risk of disease progression or death compared with standard therapy. The stud…
    BioSpace · 14d agoPositive readoutPositive↗ source
  • ArriVent BioPharma's Phase 3 lung cancer trial misses primary endpoint, shares tumble
    ArriVent BioPharma reported that its investigational EGFR tyrosine kinase inhibitor firmonertinib did not achieve a statistically significant improvement in progression-free survival in the Phase 3…
    BioSpace · 14d agoNegative readoutNegative↗ source
  • Caribou Biosciences to halt R&D and cut staff as financing for allogeneic CAR-T dries up
    Caribou Biosciences, co‑founded by Nobel laureate Jennifer Doudna, announced it will stop all clinical‑stage work and lay off staff because of a financing freeze in the allogeneic CAR‑T market. Th…
    BioSpace · 14d agoLayoffsNegative↗ source
  • Biotech VC Forbion raises record €2.3 bn ($2.6 bn) to back 30 high-potential life-science companies
    Forbion announced a record fundraising of €2.3 bn ($2.6 bn) across two new funds, bringing its assets under management to about €7.5 bn ($8.4 bn). The capital will be allocated through the Forbion…
    BioSpace · 14d agoDealPositive↗ source
  • Bayer invests $2.2 billion in Ohio to build pharma manufacturing plant
    Bayer announced a $2.2 billion investment to construct a new pharmaceutical manufacturing complex in New Albany, Ohio. The plant will produce drug substances and finished products for oncology, ca…
    BioSpace · 14d agoDealNeutral↗ source
  • Venture capital continues to flow into biopharma in Q3 2026, favoring later-stage and AI-driven companies
    Venture capital funding into biopharma topped $16 billion in the first half of 2026 and kept rising in the third quarter, according to industry sources. Investors remain selective, directing money…
    BioSpace · 14d agoDealNeutral↗ source
  • Executive candidates need full truth, not a sales pitch, to address company challenges
    The article argues that candidates for senior roles must be given an honest picture of the company's problems rather than a polished sales narrative. It notes that during executive searches, infor…
    BioSpace · 14d agoNeutral↗ source
  • Eden Brothers recalls Calabrese broccoli seeds over possible Salmonella contamination
    Eden Brothers LLC announced a recall of its Calabrese broccoli seeds after being informed by its supplier that the product may be contaminated with Salmonella. The recall includes 1‑ounce and 1‑po…
    fda recalls · 14d agoCRLNegative↗ source
  • Epkinly shows 51% PFS boost in frontline DLBCL, may become new standard of care
    AbbVie and Genmab reported that their bispecific antibody Epkinly achieved a substantial gain in progression‑free survival when added to the standard R‑CHOP regimen in newly diagnosed diffuse large…
    BioSpace · 15d agoPositive readoutPositive↗ source